Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Method of cancer treatment using sirna silencing

a cancer treatment and silencing technology, applied in the field of cancer treatment using sirna silencing, can solve the problems of renewed tumor rejection, currently used immunomodulatory drugs pose potential toxic threats to humans, and no studies have been demonstrated to support such contentions, so as to reduce the expression of said ido, and reduce the effect of ido-directed tumor immunosuppression

Active Publication Date: 2009-09-03
REGEN BIOPHARMA
View PDF1 Cites 22 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0014]According to another aspect of the present invention is a method for the treatment of cancer involving tumor derived immunosuppression in a subject, the method comprising administering to said subject one or more siRNA constructs directed to an immunosuppressive molecule selected from the group consisting of IDO-siRNA, FasL-siRNA, VEGF-siRNA, IL-10-siRNA, TRAIL-siRNA, DAF-siRNA, HLA-G-siRNA and combinations thereof said siRNA construct capable of substantially inhibiting and / or reducing the expression of said immunosuppressive molecule.
[0028]According to a further aspect of the present invention, provided is a method of increasing T-cell proliferation in a mammalian subject, wherein a therapeutically effective amount of an siRNA-IDO construct is administered to said subject, said construct targeting an endogenous IDO, reducing expression of said IDO thereby reducing IDO-directed immunosuppression and T-cell apoptosis.

Problems solved by technology

The immunosuppressive effect of IDO was completely reversed by the introduction of 1-MT (a chemical with potential toxic effects) leading to renewed tumor rejection.
In the case of IDO, currently used immunomodulatory drugs pose potential toxic threats towards humans especially if required in large doses.
WO 02 / 08644 and WO 04 / 048938 suggest that siRNA technology may be used for inhibiting cancer, however, no studies were demonstrated to support such a contention.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of cancer treatment using sirna silencing
  • Method of cancer treatment using sirna silencing
  • Method of cancer treatment using sirna silencing

Examples

Experimental program
Comparison scheme
Effect test

example 1

Materials and Methods

Animal and Cell Lines

[0098]Male C57BL / 6 and BALB / c mice were purchased from Jackson laboratories (Bar Harbour, Me.). A murine melanoma cell line established from a C57BL / 6 mouse designated B16F10 was obtained from American Type Culture Collection (ATCC, Manassas, Va.). B16 cells were cultured in RPMI1640 medium (sigma) with 10% fetal bovine serum, L-glutamine, penicillin and streptomycin at 37° C. in 5% CO2 incubator.

IDO-Specifics siRNA Expression Vectors

[0099]siRNA expression vectors were constructed using the pQuiet plasmid (Welgen Inc.). Specific IDO-siRNA inserts were designed according to manufacturer's instruction. The oligonucleotide contained a 19-mer hairpin sequences specific to the IDO mRNA target, a loop sequence separating the two complementary domains, a two nucleotide overhang at the 3′ end, a poly thymidine stretch to terminate transcription and a 5′ single-stranded overhang for ligation into the pQuiet vector using the Bgl I and Xob I cut sites....

example 2

IDO is Efficiently Silenced by siRNA in B16 Melanoma Cells

[0115]IDO has been demonstrated to be expressed in B16 melanomas. To test the efficacy of gene silencing in the B16 melanoma cell line, a liposome transfection method was incorporated to deliver our IDO-siRNA-containing pQuiet plasmid into B16 cells in vitro. Twenty four hours after transfection, potent gene silence was observed at the transcriptional level as detected by RT-PCR (FIG. 1A). The protein level of IDO was also significantly decreased as detected by Western Blotting (FIG. 1B), suggesting the expression of IDO in B16 cells could be effectively inhibited by IDO-siRNA.

[0116]Since IDO functions as a specific enzyme to primarily catabolize tryptophan, in order to characterize the effects of silencing on enzyme efficacy the change in levels of tryptophan in B16 culture medium upon silencing was detected. B16 cells silenced by siRNA displayed significantly lower IDO functionality (p<0.05) than B16 cells transfected with ...

example 3

Silencing IDO in B16 Cells Prior to Inoculation Inhibits Tumor Growth

[0117]It has been reported that IDO expression is correlated with tumor progression. Tumor cells expressing IDO produce larger and more aggressive tumors than those which have been chemically silenced of IDO expression (4). It was therefore postulated that siRNA-induced silencing of IDO in B16 cells prior to inoculation would restrain tumor growth substantially. To test this hypothesis, IDO-siRNA into B16 cells were transfected using a liposome transfection method in vitro. IDO-silenced B16 cells were then subcutaneously injected in to syngeneic C57 / BL6 mice. As demonstrated in FIG. 2A, tumor onset time in IDO-siRNA-treated mice was substantially postponed (p<0.0001) in comparison with mice injected with non-silenced or nonsense-siRNA-treated B16 cells.

[0118]In addition to tumor onset time, also observed were the sizes of tumors derived from IDO-silenced and control B16 cells. Wild-type B16 cells, as well as mock-s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
sizeaaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention is a method for the treatment of cancer involving tumor derived immunosuppression in a subject. The method comprises administering to a subject one or more siRNA constructs capable of inhibiting the expression of an immunosuppressive molecule. The invention also provides siRNA constructs and compositions.

Description

FIELD OF THE INVENTION[0001]The invention relates to a novel method for cancer therapy. More specifically, the invention is directed to the silencing of immunosuppressive cancer causing genes using short interfering RNA (siRNA) leading to an increase in the immune response, a decrease in tumor-induced immunosuppression and a decrease in in vivo tumor progression.BACKGROUND OF THE INVENTION[0002]Throughout this application, various references are cited in parentheses to describe more fully the state of the art to which this invention pertains. Full bibliographic information for each citation is found at the end of the specification, immediately preceding the claims. The disclosure of these references are hereby incorporated by reference into the present disclosure.[0003]The ability of cancer cells to evade or escape immune detection and destruction is recognized as a key hallmark of carcinogenesis and cancer progression (Rodriguez, P. C., A. H. Zea, and A. C. Ochoa. 2003. Mechanisms ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/127A61K31/7105A61K39/00C07H21/02C12N15/11C12N15/113
CPCA61K31/713C12N15/111C12N15/113C12N15/1135C12Y113/11011C12N15/1137C12N15/1138C12N2310/14C12N2320/30C12N15/1136A61P35/00
Inventor MIN, WEIPING
Owner REGEN BIOPHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com